IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kristian Reich, Kilian Eyerich, Knut Schäkel, Peter Weisenseel, Andreas Pinter, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut
Format: article
Langue:EN
Publié: BMJ Publishing Group 2021
Sujets:
Medicine
R
Accès en ligne:https://doaj.org/article/673be33cf2a54e4aba93d38bcb985891
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Documents similaires